Potential for use sunitinib in pancreatic neuroendocrine tumors
The treatment efficacy and toxicity profile was evaluated in 33 patients with highly differentiated neuroendocrine tumors NEO (G1, G2), who received sunitinib therapy in various dose regimens. Stable disease was achieved in 24 patients (72.7%), partial effect in 1 patient (3%). The efficacy of treat...
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Russo |
| Almmustuhtton: |
Remedium Group LLC
2019-06-01
|
| Ráidu: | Медицинский совет |
| Fáttát: | |
| Liŋkkat: | https://www.med-sovet.pro/jour/article/view/3061 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|